KFS
BMRN icon

Kelly Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kelly Financial Services’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20
Closed -$1.55K – 683
2021
Q3 		$1.55K Sell
20
-1,649
-99% -$130K ﹤0.01% 545
2021
Q2 		$20K Buy
1,669
+1,585
+1,887% +$126K ﹤0.01% 549
2021
Q1 		$6.34K Buy
+84
New +$6.86K ﹤0.01% 367

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Kelly Financial Services's BMRN Position: Q4 2021 in Review

Kelly Financial Services sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 20 shares — an estimated $1.55K sold.

Kelly Financial Services first reported a position in BMRN in Q1 2021 and held it in 3 quarters. The position peaked at $20K in Q2 2021. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

  • Kelly Financial Services reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Kelly Financial Services sold 20 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $1.55K.
  • Kelly Financial Services first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Kelly Financial Services's BioMarin Pharmaceuticals position peaked at $20K in Q2 2021.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Kelly Financial Services's 13F filing for Q4 2021, filed 17 Jul 2024.